Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive dynamic of the U.

Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their purpose is to address unmet needs in serious chronic disease and a holistic approach is necessary.